| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 52 | 2023 | 1018 | 13.180 |
Why?
|
| Lung Neoplasms | 75 | 2023 | 2168 | 12.460 |
Why?
|
| Pneumonectomy | 22 | 2022 | 191 | 6.510 |
Why?
|
| Thoracic Surgery | 8 | 2022 | 40 | 3.480 |
Why?
|
| Neoplasm Staging | 37 | 2023 | 1883 | 3.330 |
Why?
|
| Osteopontin | 6 | 2013 | 48 | 2.130 |
Why?
|
| Radiosurgery | 9 | 2021 | 262 | 1.880 |
Why?
|
| Physicians, Women | 5 | 2022 | 50 | 1.720 |
Why?
|
| Thoracic Surgical Procedures | 4 | 2022 | 42 | 1.710 |
Why?
|
| Surgeons | 5 | 2021 | 190 | 1.630 |
Why?
|
| Specialties, Surgical | 2 | 2021 | 59 | 1.560 |
Why?
|
| Humans | 125 | 2023 | 80897 | 1.510 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2022 | 27 | 1.480 |
Why?
|
| Adenocarcinoma | 11 | 2016 | 1125 | 1.390 |
Why?
|
| Early Detection of Cancer | 4 | 2022 | 350 | 1.320 |
Why?
|
| Pleural Neoplasms | 11 | 2016 | 184 | 1.250 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2023 | 94 | 1.210 |
Why?
|
| Mesothelioma | 13 | 2016 | 289 | 1.200 |
Why?
|
| Esophagectomy | 5 | 2009 | 74 | 1.190 |
Why?
|
| Disease Management | 3 | 2019 | 317 | 0.950 |
Why?
|
| Catheter Ablation | 6 | 2015 | 216 | 0.950 |
Why?
|
| Jehovah's Witnesses | 1 | 2022 | 18 | 0.930 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2020 | 2440 | 0.930 |
Why?
|
| Neoadjuvant Therapy | 6 | 2022 | 274 | 0.910 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 1219 | 0.880 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 1409 | 0.850 |
Why?
|
| Symptom Assessment | 1 | 2020 | 54 | 0.800 |
Why?
|
| Esophageal Neoplasms | 4 | 2009 | 304 | 0.790 |
Why?
|
| Antibody Formation | 1 | 2020 | 169 | 0.790 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 292 | 0.770 |
Why?
|
| Combined Modality Therapy | 11 | 2022 | 1613 | 0.760 |
Why?
|
| Immunotherapy | 5 | 2022 | 570 | 0.750 |
Why?
|
| Robotic Surgical Procedures | 2 | 2022 | 225 | 0.740 |
Why?
|
| Surgical Flaps | 3 | 2017 | 245 | 0.740 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2022 | 446 | 0.740 |
Why?
|
| Societies, Medical | 3 | 2020 | 564 | 0.740 |
Why?
|
| Mass Screening | 3 | 2022 | 597 | 0.730 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2016 | 1045 | 0.710 |
Why?
|
| Neoplasms, Second Primary | 5 | 2016 | 247 | 0.680 |
Why?
|
| Radium | 3 | 2021 | 6 | 0.640 |
Why?
|
| Probability | 1 | 2017 | 344 | 0.620 |
Why?
|
| Skin Ulcer | 1 | 2016 | 25 | 0.620 |
Why?
|
| Salvage Therapy | 2 | 2017 | 227 | 0.620 |
Why?
|
| Female | 43 | 2022 | 42456 | 0.600 |
Why?
|
| Treatment Outcome | 13 | 2022 | 7492 | 0.600 |
Why?
|
| Hyaluronan Receptors | 2 | 2013 | 38 | 0.580 |
Why?
|
| Frozen Sections | 1 | 2015 | 47 | 0.580 |
Why?
|
| Skin Transplantation | 1 | 2016 | 170 | 0.570 |
Why?
|
| Prognosis | 16 | 2021 | 3544 | 0.560 |
Why?
|
| Male | 38 | 2021 | 39412 | 0.560 |
Why?
|
| Middle Aged | 31 | 2021 | 23961 | 0.560 |
Why?
|
| Esophagus | 2 | 2006 | 101 | 0.550 |
Why?
|
| Monitoring, Intraoperative | 1 | 2015 | 107 | 0.550 |
Why?
|
| United States | 13 | 2022 | 6169 | 0.520 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2012 | 124 | 0.520 |
Why?
|
| Aged | 26 | 2022 | 17475 | 0.520 |
Why?
|
| Radiopharmaceuticals | 3 | 2012 | 159 | 0.510 |
Why?
|
| Pancoast Syndrome | 1 | 2013 | 2 | 0.510 |
Why?
|
| Fas Ligand Protein | 1 | 2013 | 49 | 0.480 |
Why?
|
| Positron-Emission Tomography | 5 | 2013 | 277 | 0.480 |
Why?
|
| Adult | 27 | 2022 | 24636 | 0.460 |
Why?
|
| Fluorine Radioisotopes | 1 | 2012 | 13 | 0.450 |
Why?
|
| Retrospective Studies | 13 | 2023 | 7560 | 0.450 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 512 | 0.450 |
Why?
|
| Radiation Injuries | 2 | 2010 | 154 | 0.440 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 98 | 0.440 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 102 | 0.420 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 204 | 0.420 |
Why?
|
| Bronchogenic Cyst | 1 | 2010 | 5 | 0.420 |
Why?
|
| Thoracic Wall | 1 | 2010 | 22 | 0.410 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 22 | 0.410 |
Why?
|
| Thoracic Diseases | 1 | 2010 | 25 | 0.410 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 1142 | 0.390 |
Why?
|
| Risk Assessment | 7 | 2022 | 2171 | 0.380 |
Why?
|
| Simulation Training | 2 | 2021 | 83 | 0.380 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2022 | 285 | 0.370 |
Why?
|
| Survival Analysis | 4 | 2019 | 1512 | 0.370 |
Why?
|
| Education, Medical, Graduate | 3 | 2020 | 344 | 0.370 |
Why?
|
| Health Status Disparities | 1 | 2011 | 155 | 0.350 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 530 | 0.340 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 6214 | 0.320 |
Why?
|
| Survival Rate | 9 | 2021 | 1811 | 0.310 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 335 | 0.300 |
Why?
|
| Dumping Syndrome | 1 | 2006 | 5 | 0.300 |
Why?
|
| Gastric Emptying | 1 | 2006 | 22 | 0.300 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2274 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 558 | 0.290 |
Why?
|
| Stomach | 1 | 2006 | 108 | 0.280 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2006 | 82 | 0.280 |
Why?
|
| Esophageal Diseases | 1 | 2005 | 25 | 0.280 |
Why?
|
| Transcription Factors | 1 | 2013 | 1485 | 0.280 |
Why?
|
| Deglutition Disorders | 1 | 2006 | 99 | 0.270 |
Why?
|
| Patient Selection | 3 | 2020 | 661 | 0.270 |
Why?
|
| Patient Care Management | 2 | 2020 | 31 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 302 | 0.270 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 286 | 0.270 |
Why?
|
| Consensus | 3 | 2021 | 296 | 0.260 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 137 | 0.260 |
Why?
|
| General Surgery | 1 | 2007 | 215 | 0.260 |
Why?
|
| Risk Factors | 5 | 2022 | 5137 | 0.260 |
Why?
|
| Gastroesophageal Reflux | 1 | 2006 | 111 | 0.260 |
Why?
|
| Computer Simulation | 3 | 2021 | 1045 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2011 | 2346 | 0.250 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 101 | 0.240 |
Why?
|
| Hamartoma | 1 | 2003 | 31 | 0.240 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2014 | 10 | 0.240 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 466 | 0.240 |
Why?
|
| Medical Oncology | 1 | 2007 | 331 | 0.240 |
Why?
|
| Chylous Ascites | 1 | 2022 | 6 | 0.230 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2002 | 30 | 0.230 |
Why?
|
| Chylothorax | 1 | 2022 | 7 | 0.230 |
Why?
|
| Lung | 4 | 2022 | 1092 | 0.230 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 1036 | 0.220 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 39 | 0.210 |
Why?
|
| ErbB Receptors | 2 | 2022 | 473 | 0.210 |
Why?
|
| Funnel Chest | 1 | 2021 | 5 | 0.210 |
Why?
|
| Pneumothorax | 2 | 2020 | 49 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 103 | 0.210 |
Why?
|
| Lung Diseases | 1 | 2003 | 255 | 0.210 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 35 | 0.210 |
Why?
|
| Chemoradiotherapy | 2 | 2020 | 296 | 0.210 |
Why?
|
| Immunization, Passive | 1 | 2020 | 69 | 0.200 |
Why?
|
| SEER Program | 2 | 2011 | 180 | 0.200 |
Why?
|
| Pandemics | 3 | 2021 | 628 | 0.200 |
Why?
|
| Lung Transplantation | 1 | 2022 | 168 | 0.200 |
Why?
|
| Critical Pathways | 1 | 2020 | 32 | 0.190 |
Why?
|
| Betacoronavirus | 2 | 2020 | 245 | 0.190 |
Why?
|
| Case-Control Studies | 4 | 2013 | 1742 | 0.190 |
Why?
|
| Sexual Harassment | 1 | 2019 | 8 | 0.190 |
Why?
|
| Riots | 1 | 2019 | 1 | 0.190 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 243 | 0.190 |
Why?
|
| Career Choice | 1 | 2021 | 136 | 0.190 |
Why?
|
| Protein Isoforms | 2 | 2010 | 260 | 0.180 |
Why?
|
| Drainage | 1 | 2020 | 141 | 0.180 |
Why?
|
| Sexism | 1 | 2019 | 39 | 0.180 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2018 | 9 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 809 | 0.180 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 24 | 0.180 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 444 | 0.170 |
Why?
|
| Thoracotomy | 1 | 2018 | 55 | 0.170 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1509 | 0.170 |
Why?
|
| Cohort Studies | 5 | 2012 | 2583 | 0.170 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 161 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 561 | 0.170 |
Why?
|
| Respiratory System | 1 | 2018 | 113 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 422 | 0.160 |
Why?
|
| Wound Closure Techniques | 1 | 2017 | 12 | 0.160 |
Why?
|
| Safety-net Providers | 1 | 2018 | 36 | 0.160 |
Why?
|
| Consolidation Chemotherapy | 1 | 2017 | 21 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 418 | 0.160 |
Why?
|
| Thoracic Neoplasms | 1 | 2017 | 60 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 56 | 0.150 |
Why?
|
| Lymph Nodes | 2 | 2011 | 509 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 4 | 2016 | 85 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1539 | 0.150 |
Why?
|
| Asbestos | 2 | 2012 | 22 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 68 | 0.140 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 128 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 172 | 0.140 |
Why?
|
| Biopsy | 2 | 2016 | 1126 | 0.140 |
Why?
|
| Forecasting | 1 | 2016 | 305 | 0.140 |
Why?
|
| Apoptosis | 2 | 2013 | 1645 | 0.140 |
Why?
|
| Subcutaneous Emphysema | 1 | 2014 | 6 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 1995 | 94 | 0.140 |
Why?
|
| Simian virus 40 | 4 | 1998 | 35 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 861 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2012 | 326 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1220 | 0.130 |
Why?
|
| Radiography | 2 | 2014 | 790 | 0.130 |
Why?
|
| Receptor, EphB2 | 1 | 2013 | 2 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 516 | 0.130 |
Why?
|
| Microbiota | 1 | 2018 | 332 | 0.120 |
Why?
|
| Peritoneum | 1 | 2013 | 47 | 0.120 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 144 | 0.120 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 24 | 0.120 |
Why?
|
| Operative Time | 1 | 2013 | 111 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2284 | 0.120 |
Why?
|
| Clinical Protocols | 1 | 2013 | 153 | 0.120 |
Why?
|
| ROC Curve | 2 | 2012 | 734 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 75 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2013 | 772 | 0.120 |
Why?
|
| Epithelium | 1 | 2013 | 309 | 0.110 |
Why?
|
| Pain Management | 1 | 2013 | 119 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2020 | 2064 | 0.110 |
Why?
|
| Cytokines | 3 | 2022 | 748 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2007 | 158 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2012 | 121 | 0.110 |
Why?
|
| Biomarkers | 2 | 2016 | 1603 | 0.110 |
Why?
|
| Occupational Exposure | 1 | 2012 | 75 | 0.110 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2013 | 136 | 0.110 |
Why?
|
| Job Satisfaction | 1 | 2012 | 71 | 0.110 |
Why?
|
| Perfusion | 2 | 2022 | 186 | 0.110 |
Why?
|
| Palliative Care | 1 | 2013 | 234 | 0.110 |
Why?
|
| Young Adult | 5 | 2021 | 5725 | 0.110 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2011 | 25 | 0.110 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 39 | 0.100 |
Why?
|
| Sternoclavicular Joint | 1 | 2010 | 2 | 0.100 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2010 | 8 | 0.100 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 40 | 0.100 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 35 | 0.100 |
Why?
|
| Mutation | 1 | 2022 | 3792 | 0.100 |
Why?
|
| Ribonucleases | 1 | 2011 | 92 | 0.100 |
Why?
|
| Debridement | 1 | 2010 | 56 | 0.100 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 43 | 0.100 |
Why?
|
| Functional Laterality | 1 | 2011 | 193 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1363 | 0.100 |
Why?
|
| Models, Anatomic | 1 | 2011 | 89 | 0.100 |
Why?
|
| Cell Movement | 2 | 2013 | 735 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 61 | 0.100 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 96 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 3 | 2009 | 1031 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2011 | 2324 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 680 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2011 | 274 | 0.100 |
Why?
|
| Necrosis | 1 | 2010 | 189 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2019 | 928 | 0.100 |
Why?
|
| Joint Diseases | 1 | 2010 | 47 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2012 | 133 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 3533 | 0.100 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 218 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2018 | 3926 | 0.100 |
Why?
|
| Tracheal Neoplasms | 1 | 2009 | 8 | 0.100 |
Why?
|
| Glomus Tumor | 1 | 2009 | 8 | 0.100 |
Why?
|
| Chest Pain | 1 | 2009 | 36 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2010 | 67 | 0.090 |
Why?
|
| Tuberculosis | 1 | 2010 | 99 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2011 | 214 | 0.090 |
Why?
|
| Endosonography | 1 | 2010 | 92 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2010 | 413 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 373 | 0.090 |
Why?
|
| Length of Stay | 2 | 2020 | 656 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 2 | 2005 | 44 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2011 | 511 | 0.090 |
Why?
|
| Time Factors | 3 | 2012 | 5094 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2013 | 1931 | 0.090 |
Why?
|
| Microwaves | 1 | 2008 | 25 | 0.080 |
Why?
|
| Wound Healing | 1 | 2010 | 336 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 370 | 0.080 |
Why?
|
| Radiation Oncologists | 2 | 2018 | 13 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2011 | 422 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 371 | 0.080 |
Why?
|
| Chest Tubes | 2 | 2020 | 22 | 0.080 |
Why?
|
| Sex Factors | 1 | 2011 | 1021 | 0.080 |
Why?
|
| DNA, Viral | 2 | 1998 | 264 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 2 | 1998 | 44 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 336 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2010 | 1328 | 0.080 |
Why?
|
| Pulmonary Ventilation | 1 | 2006 | 32 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 450 | 0.080 |
Why?
|
| Cognition | 1 | 2011 | 500 | 0.080 |
Why?
|
| Sialoglycoproteins | 1 | 2006 | 32 | 0.070 |
Why?
|
| Carbonic Anhydrases | 1 | 2006 | 12 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1183 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2006 | 170 | 0.070 |
Why?
|
| Mediastinoscopy | 1 | 2005 | 5 | 0.070 |
Why?
|
| Thoracic Injuries | 1 | 2006 | 29 | 0.070 |
Why?
|
| Peritoneal Neoplasms | 2 | 1998 | 152 | 0.070 |
Why?
|
| California | 1 | 2006 | 134 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2017 | 169 | 0.070 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 9 | 0.070 |
Why?
|
| Esophagoplasty | 1 | 2005 | 10 | 0.070 |
Why?
|
| Anesthetics | 1 | 2005 | 47 | 0.070 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 485 | 0.070 |
Why?
|
| Blood Loss, Surgical | 1 | 2005 | 106 | 0.070 |
Why?
|
| Risk | 1 | 2006 | 667 | 0.070 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 317 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 8669 | 0.060 |
Why?
|
| Incidence | 2 | 2022 | 1540 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2005 | 382 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 18 | 0.060 |
Why?
|
| Work-Life Balance | 1 | 2022 | 6 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2022 | 73 | 0.060 |
Why?
|
| Smoking | 1 | 2006 | 594 | 0.060 |
Why?
|
| Asthma | 1 | 2009 | 913 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2003 | 322 | 0.050 |
Why?
|
| Leukocytes | 1 | 2022 | 192 | 0.050 |
Why?
|
| Transfection | 3 | 2011 | 885 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2021 | 110 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2020 | 720 | 0.050 |
Why?
|
| Oxygen | 1 | 2006 | 706 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 145 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 66 | 0.050 |
Why?
|
| Child | 2 | 2022 | 6544 | 0.050 |
Why?
|
| Bioethics | 1 | 2020 | 31 | 0.050 |
Why?
|
| Epitopes | 1 | 2021 | 253 | 0.050 |
Why?
|
| Risk Management | 1 | 2020 | 43 | 0.050 |
Why?
|
| Etoposide | 1 | 2020 | 192 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1013 | 0.050 |
Why?
|
| Bias | 1 | 2020 | 125 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2019 | 36 | 0.050 |
Why?
|
| Medicare | 1 | 2022 | 332 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 209 | 0.050 |
Why?
|
| Asbestosis | 2 | 1998 | 5 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2021 | 250 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 124 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2022 | 419 | 0.050 |
Why?
|
| Living Donors | 1 | 2022 | 309 | 0.040 |
Why?
|
| Sputum | 1 | 2018 | 31 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 107 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 79 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2021 | 466 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2018 | 122 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 499 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1998 | 68 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1998 | 142 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 270 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 220 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 795 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 142 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 1996 | 16 | 0.040 |
Why?
|
| Liver | 1 | 2022 | 1187 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 1996 | 725 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 1996 | 10 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 198 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 1939 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 915 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2018 | 300 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 197 | 0.040 |
Why?
|
| Anniversaries and Special Events | 1 | 2016 | 14 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 723 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 1998 | 234 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2021 | 731 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 1995 | 113 | 0.040 |
Why?
|
| Radiation Oncology | 1 | 2017 | 121 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1995 | 104 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1995 | 157 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1995 | 169 | 0.030 |
Why?
|
| Base Sequence | 2 | 1996 | 2313 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1995 | 147 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 304 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 646 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 1995 | 381 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 506 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3026 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1713 | 0.030 |
Why?
|
| DNA Damage | 1 | 1995 | 350 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 1995 | 334 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 299 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 308 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2012 | 44 | 0.030 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2012 | 14 | 0.030 |
Why?
|
| Cricetinae | 3 | 1998 | 559 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 449 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 265 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 678 | 0.030 |
Why?
|
| Fear | 1 | 2012 | 67 | 0.030 |
Why?
|
| Self Concept | 1 | 2012 | 128 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 1118 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 538 | 0.030 |
Why?
|
| Thoracoscopes | 1 | 2011 | 2 | 0.030 |
Why?
|
| Surgical Staplers | 1 | 2011 | 10 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 317 | 0.030 |
Why?
|
| Taxoids | 1 | 2011 | 128 | 0.030 |
Why?
|
| Dissection | 1 | 2011 | 42 | 0.030 |
Why?
|
| Computer Graphics | 1 | 2011 | 100 | 0.030 |
Why?
|
| Motor Skills | 1 | 2011 | 69 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2010 | 35 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2011 | 57 | 0.020 |
Why?
|
| Carboplatin | 1 | 2011 | 281 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 842 | 0.020 |
Why?
|
| Mediastinum | 1 | 2010 | 46 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 377 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 961 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 232 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 497 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 948 | 0.020 |
Why?
|
| Depression | 1 | 2012 | 421 | 0.020 |
Why?
|
| Empyema | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2773 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2006 | 1163 | 0.020 |
Why?
|
| Plasmids | 2 | 1998 | 279 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1998 | 114 | 0.020 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2006 | 9 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 20 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 585 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2005 | 35 | 0.020 |
Why?
|
| Tracheal Diseases | 1 | 2005 | 12 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1778 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 922 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1605 | 0.020 |
Why?
|
| Animals | 4 | 1998 | 25628 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 2583 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 254 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 1435 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1998 | 90 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 309 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1998 | 110 | 0.010 |
Why?
|
| Oxygenators | 1 | 1996 | 3 | 0.010 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 1996 | 27 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 1996 | 42 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1996 | 151 | 0.010 |
Why?
|
| Hyperthermia, Induced | 1 | 1996 | 53 | 0.010 |
Why?
|
| Safety | 1 | 1996 | 152 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1998 | 406 | 0.010 |
Why?
|
| Cell Division | 1 | 1996 | 689 | 0.010 |
Why?
|
| Sarcoma | 1 | 1996 | 205 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 1996 | 285 | 0.010 |
Why?
|
| Remission Induction | 1 | 1996 | 705 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1996 | 437 | 0.010 |
Why?
|
| Melanoma | 1 | 1996 | 431 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1996 | 402 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1116 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1996 | 1107 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 3904 | 0.010 |
Why?
|